Cboe AU - Delayed Quote AUD

SomnoMed Limited (SOM.XA)

Compare
0.0000 -0.2400 (-100.00%)
At close: November 22 at 1:19 PM GMT+11
Loading Chart for SOM.XA
DELL
  • Previous Close 0.2400
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 0.5300
  • Volume 0
  • Avg. Volume 9,034
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 1.38
  • PE Ratio (TTM) -0.00
  • EPS (TTM) -0.0590
  • Earnings Date Oct 23, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. In addition, it provides Sunrise, a bio-signal to diagnose sleep apnea. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.

somnomed.com/au/

--

Full Time Employees

June 30

Fiscal Year Ends

--

Sector

--

Industry

Recent News: SOM.XA

View More

Performance Overview: SOM.XA

Trailing total returns as of 11/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SOM.XA
0.00%
MSCI WORLD
18.83%

1-Year Return

SOM.XA
0.00%
MSCI WORLD
25.17%

3-Year Return

SOM.XA
0.00%
MSCI WORLD
17.80%

5-Year Return

SOM.XA
0.00%
MSCI WORLD
65.62%

Compare To: SOM.XA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SOM.XA

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -13.36%

  • Return on Assets (ttm)

    -7.86%

  • Return on Equity (ttm)

    -36.31%

  • Revenue (ttm)

    91.65M

  • Net Income Avi to Common (ttm)

    -12.24M

  • Diluted EPS (ttm)

    -0.0590

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.18M

  • Total Debt/Equity (mrq)

    14.93%

  • Levered Free Cash Flow (ttm)

    -6.86M

Research Analysis: SOM.XA

View More

Company Insights: SOM.XA

Research Reports: SOM.XA

View More